Literature 1-240

1 Swiss Drug Compendium / Arzneimittel Kompendium der Schweiz / Compendium des médicaments de la Suisse. HCI Solutions Ltd., Bern, Switzerland. Online access 2008 until today.
2 Neonatal and Pediatric Pharmacology, 3rd and 4th edition. Yaffe SJ et al. (editors). Lippincott Williams & Wilkins, Philadelphia, USA, 2005 and 2011.
3 Problems in Pediatric Drug Therapy, 4th edition. Pagliaro LA et al. (editors). Drug intelligence publications, Hamilton, USA, 2002.
4 Drug Information: American hospital formulary service. McEvoy GK et al. (editors). American Society of Health-system Pharmacists, Bethesda, USA, 1995.
6 Information of manufacturer or sales company / Information des Herstellers oder der Vertriebsfirma / Information du fabricant ou de l’entreprise
7 Dosing recommendation of University Children’s Hospital Zurich, not cited in inhouse leaflets / Dosierungsempfehlungen des Universitäts-Kinderspitals Zürich, ohne Erwähnung in internen Merkblättern / Recommandations de posologies au l’Hôpital universitaire d’Enfants Zurich, non-indiquées dans les notices d’utilisation internes.
7a Dosing recommendation and documents of University Children’s Hospital Zurich, cited in inhouse leaflets / Dosierungsempfehlungen des Universitäts-Kinderspitals Zürich, mit Erwähnung in internen Merkblättern / Recommandations de posologies au l’Hôpital universitaire d’Enfants Zurich, indiquées dans les notices d’utilisation internes.
8 Drug Doses, 14th and 15th edition. Shann F. Royal Children’s Hospital, Victoria, Australia, 2008 and 2010.
9 Red Book 2018-2021: Report of the Committee on Infectious Diseases, 31st edition. Kimberlin DW (editor). American Academy of Pediatrics, Itasca, USA, 2018.
10 Laboratory analyses, analysis files / Laboranalysen, Analysen-Kartei / Analyses de laboratoire, fichier d’analyses. University Children’s Hospital Zurich. Infopoint intranet, January 2008 until today.
11 Päd i.v.: Sichere Anwendung von intravenösen Arzneimitteln bei Kindern, 2. Auflage. Frey O et al. Die Deutsche Bibliothek, 2002.
12 Labor und Diagnose: Indikation und Bewertung von Laborbefunden für die medizinische Diagnostik, 7. Auflage. Thomas L (Herausgeber). TH-Books-Verlags-Gesellschaft, Frankfurt/Main, Deutschland, 2008.
13 Product Information for healthcare professionals from outside of Switzerland / Fachinformation ausserhalb der Schweiz / Information professionnelle hors de la Suisse
16 Flückiger U et al. Revidierte schweizerische Richtlinien für die Endokarditis-Prophylaxe. Kardiovaskuläre Medizin 2008; 11(12): 392-400.
17 Laboratory specifications of the University Hospital Zurich / Laborangaben des Universitätsspitals Zürich / Indication du laboratoire de l’hôpital universitaire de Zurich
20 Benkebil F et al. Anwendung und Toxizität von peroralem flüssigem Paraffin beim Kind. Paediatrica 2006; 17(5): 25-27.
21 Bundesamt für Gesundheit BAG (editor). Prävention von invasiven Meningokokkeninfektionen. Empfehlungen der Schweizerischen Kommission für Impffragen, der Arbeitsgruppe Menigokokken und des Bundesamtes für Gesundheit. BAG-Bulletin 2001; 46: 893-901.
22 Bundesamt für Gesundheit BAG (editor).
Antidote bei Vergiftungen 2009. BAG-Bulletin 2009; 11: 175-88 and
Antidote bei Vergiftungen 2012. BAG-Bulletin 2012; 17: 274-90 and
Antidote bei Vergiftungen 2013. BAG-Bulletin 2013; 30: 507-21 and
Antidote bei Vergiftungen further issues online access 2014 until today.
23 Özkaya N et al. Colchicine treatment in children with familial mediterranean fever. Clin Rheumatol 2003; 22(4-5): 314-7 (PMID: 14579163).
24 Jeanneret B et al. Hochdosiertes Methylprednisolon in der Behandlung des akut Querschnittverletzten. Schweiz Med Forum 2008; 8(14): 258-9.
25 Fishbane S. Iron treatment: impact of safety issues. Am J Kidney Dis 1998; 32(6 Suppl 4): S152-6 (PMID: 9892383).
26 Bax R. Development of a twice daily dosing regimen of amoxicillin/clavulanate. Int J Antimicrob Agents 2007; 30(Suppl 2): 118-21 (PMID: 17983732).
27 Hoberman A et al. Equivalent efficacy and reduced occurrence of diarrhoea from a new formulation of amoxicillin/clavulanate potassium (Augmentin) for treatment of acute otitis media in children. Pediatr Infect Dis J 1997; 16(5): 463-70 (PMID: 9154538).
28 Damrikarnlert L et al. Efficacy and safety of amoxycillin/clavulanate (Augmentin) twice daily versus three times daily in the treatment of acute otitis media in children. The Augmentin 454 Study Group. J Chemother 2000; 12(1): 79-87 (PMID: 10768519).
29 Handbook of Pediatric Cardiovascular Drugs, 1st and 2nd edition. Munoz R et al. (editors). Springer Verlag, London, UK, 2008 and 2014.
30 Kenney RL et al. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007; 22(2): 193-7 (PMID: 17133512).
31 Treatment of Dystonia in movement disorders - neurologic principles and practice, 2nd edition. Watts RL et al. McGraw-Hill Companies, 2004.
32 Physician's Guide to the Treatment and Follow-Up of Metabolic Diseases. Blau N et al. (editors). Springer Verlag, 2006.
33 Cheung MS et al. Osteogenesis imperfecta: update on presentation and management. Rev Endocr Metab Disord 2008; 9(2): 153-60 (PMID: 18404382).
34 Bundesamt für Gesundheit BAG (editor). Bundesamt für Gesundheit und Eidgenössische Kommission für Impffragen, Richtlinien und Empfehlungen.
Schweizerischer Impfplan 2009; online access 03-05/2009 and
Schweizerischer Impfplan 2012; online access 09-11/2012 and
Schweizerischer Impfplan 2015; online access 03/2015 and
Schweizerischer Impfplan further issues, online access until today.
35 Patient information leaflet, package leaflet / Patienteninformation, Beipackzettel / Information des patients, notice d’emballage
36 Product label / Produkte Etikette / Etiquette du produit
37 Trachte AL et al. Oral sildenafil reduces pulmonary hypertension after cardiac surgery. Ann Thorac Surg 2005; 79(1): 194-7 (PMID: 15620942).
38 Spring RM et al. Sildenafil for pulmonary hypertension: dose-dependent improvement in exercise performance. Pulm Pharmacol Ther 2008; 21(3): 516-21 (PMID: 18249145).
39 Hoeper MM et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342(25):1866-70 (PMID: 10861321).
40 Phillips JA et al. Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia. Intern Med J 2001; 31(1): 23-6 (PMID: 11478352).
41 Petri M. Cyclophosphamide: new approaches for systemic lupus erythematosus. Lupus 2004; 13(5): 366-71 (PMID: 15230294).
42 Ruperto N Lovell DJ et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007; 56(9): 3096-106 (PMID: 17763439).
43 Lovell DJ et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359(8): 810-20 (PMID: 18716298).
44 Sameri RM et al. Lower serum digoxin concentrations in heart failure and reassessment of laboratory report forms. Am J Med Sci 2002; 324(1):10-3 (PMID: 12120820).
45 Patel P et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update. Pediatr Blood Cancer 2017; 64(10): e26542 (PMID: 28453189).
46 Gantenbein MH et al. Side effects of angiotensin converting enzyme inhibitor (captopril) in newborns and young infants. J Perinat Med 2008; 36(5): 448-52 (PMID: 18605972).
48 Büttiker V et al. Somatostatin: a new therapeutic option for the treatment of chylothorax. Intensive Care Med 2001; (27): 1083-6 (PMID: 11497142).
49 Burri S et al. Efficacy and safety of intravenous amiodarone for incessant tachycardias in infants. Eur J Pediatr 2003; 162(12): 880-4 (PMID: 14508682).
50 De Luca A et al. Zytochrome und ihre Bedeutung für Arzneimittelinteraktionen. pharma-kritik, Infomed-Verlags-AG, 3. Auflage, Wil, 2003.
51 British National Formulary for Children, 2005 and 2011-2012. Royal Pharmaceutical Society of Great Britain, Pharmaceutical Press, Bedfordshire, United Kingdom.
52 Arzneimittelwirkungen: Lehrbuch der Pharmakologie und Toxikologie, 8. Auflage. Mutschler E et al. Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2001.
53 Optimale Routenwahl der Schmerzmedikation. Schweizerische Gesellschaft zum Studium des Schmerzens. Online access 02/2009.
54 Hoffmann GF et al. Pyridoxal 5’-phosphate may be curative in early-onset epileptic encephalopathy. J Inherit Metab Dis 2007; 30(1): 96-9 (PMID: 17216302).
55 Rote Liste, Arzneimittelverzeichnis Deutschland. Online access 2008 until today.
56 Arzneimittel Kompendium der Schweiz 2002, Documed AG, Basel, Switzerland, 2001.
57 Drug Monitoring - Leitfaden für die klinische Praxis, 2. Auflage. Evans WE et al. Abbott GmbH Diagnostica, Wiesbaden, 1994.
58 Dosing - Informationen zur Arzneimittel-Anwendung und -Sicherheit. Haefeli WE. Online access 2008 until today.
59 Klugman KP et al. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem meningitis study group. Antimicrob Agents Chemother 1995; 39(5): 1140-6 (PMID: 7625802).
60 Schmutzhard E et al. A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem meningitis study group. J Antimicrob Chemother 1995; 36 Suppl A: 85-97 (PMID: 8543502).
61 Safetravel – Reisemedizinische Beratung. Online access 2009 until today.
62 World Health Organisation (editor). Guidelines for the treatment of malaria, 2006 (online access 2009) und Guidelines for the treatment of malaria, 2nd edition, 2010 (online access 09-11/2012).
63 Pullen J et al. Protein binding of flucloxacillin in neonates. Ther Drug Monit 2007; 29(3): 279-83 (PMID: 17529883).
64 Pullen J et al. Population pharmacokinetics and dosing of flucloxacillin in preterm and term neonates. Ther Drug Monit 2006; 28(3): 351-8 (PMID: 16778719).
65 Walsh TJ et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60 (PMID: 18177225).
66 Sampson HA et al. Second symposium on the definition and management of anaphylaxis: summary report- second national institute of allergy and infectious disease/food allergy and anaphylaxis network symposium. J Allergy Clin Immunol 2006; 117(2): 391-7 (PMID: 16461139).
67 Arnon S et al. The efficacy and safety of early supplementation of iron polymaltose complex inpreterm infants. Am J Perinatol 2007; 24(2): 95-100 (PMID: 17304425).
68 Food and Drug Administration FDA. MedWatch Safety Information, 06/2009.
69 Lorenz J. Information of Roche Pharma Switzerland referred to Periodical Safety Update Report (PSUR), 05/2010.
70 Sarrell EM et al. Antipyretic treatment in young children with fever: acetaminophen, ibuprofen or both alternating in a randomized, double-blind study. Arch Pediatr Adolesc Med 2006; 160(2): 197-202 (PMID: 16461878).
71 Handbook of emergency cardiovascular care for healthcare providers. Chapter: Pediatric advanced life support drugs (PALS). American Heart Association, 2010.
72 Barst RJ et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertention. Circulation 2012; 125: 324-34 (PMID: 22128226).
73 Verabreichung von Medikamenten via Sonde. Kantonsspitalapotheke Winterthur, 2005.
74 Medikamente und enterale Ernährung, Spitalapotheke Spital Solothurn, 2005.
75 Zermörserbarkeit und Verabreichungshinweise von Tabletten, Universitätsspital Basel, Institut für Spitalpharmazie, 2008 and 2012.
76 Arzneimitteleinnahme, Apotheke Lindenhofspital Bern, 2008.
77 Recommandation d’utilisation, Pharmacie des Hôpitaux Universitaires de Genève, 2005.
78 Information of companies about dividing, crushing, dispersing or solubilizing oral solid drug formulations / Informationen von Firmen zur Teilbarkeit, Zermörserbarkeit, Dispensierung oder Auflösung von oralen festen Arzneiformen / Information des entreprises sur la sécabilité, possibilité de broyage, de mise en suspension ou en dissolution des médicaments oraux solides.
79 GSASA-Fragebogen: Fasturtec, Sanofi Aventis, 04/2003.
81 Apotheken-Handbuch der Schweiz (pharManuel), Ausgabe 2001 / 2002. PharmaSuisse (Dachverband Schweizer ApothekerInnen), Bern-Liebefeld, Schweiz.
82 Engler F et al. Treatment with sulthiame (Ospolot) in benign partial epilepsy of childhood and related syndromes: an open clinical and EEG study. Neuropediatrics 2003; 34(2): 105-9 (PMID: 12776234).
83 Ritter F et al. Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures. Epilepsia 2000; 41(Suppl. l): S82-5 (PMID: 10768307).
84 Foeldvari I et al. A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis. J Rheumatol 2009; 36(1): 174-82 (PMID: 19012356).
85 Pharmavista – Information for Healthcare Professionals. HCI Solutions Ltd, Bern, Switzerland. Online access.
87 Zytostatika Herstellung in der Apotheke. Barth J. Deutscher Apotheker Verlag Stuttgart, 2003-2011.
88 The Cytotoxics Handbook; 4th edition. Allwood M et al. Radcliffe Medical Press, Oxon 2002.
89 Deutsches Arzneibuch DAB, 9. Ausgabe. Deutscher Apotheker Verlag, Stuttgart 1986.
90 Handbuch Tuberkulose. Barben et al. Lungenliga Schweiz und Bundesamt für Gesundheit, Lungenliga Schweiz, Bern, 2011.
91 Bisgaard H et al. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest 2006; 130(6): 1733-43 (PMID: 17166990).
92 Braido F et al. Towards the grade of recommendations, assessment, development and evaluation system: methods and results of budesonide/formoterol maintenance and reliever therapy research. Curr Opin Allergy Clin Immunol 2011; 11(4): 361-74 (PMID: 21659859).
93 Louis R et al. A comparison of budesonide/formoterol maintenance and reliever therapy vs. conventional best practice in asthma management. Int J Clin Pract 2009; 63(10): 1479-88 (PMID: 19769705).
94 Largent V et al. Bleeding diathesis in a child with normal screening tests: think about fibrinolysis. Eur J Pediatr 2005; 164: 587-8 (PMID: 15940466).
95 Davenport M. Biliary atresia: clinical aspects. Semin Pediatr Surg 2012; 21: 175-84 (PMID: 22800970).
96 Dulac O et al. Sodium valproate monotherapy in childhood epilepsy. Brain Dev 1986; 8: 47-52 (PMID: 3085530).
97 Grimwood K et al. Antibiotic management of pneumococcal infections in an era of increased resistance. J Paediatr Child Health 1997; 33: 287-95 (PMID: 9323614).
98 Elterman RD et al. Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001; 57: 1416-21 (PMID: 11673582).
99 Sinaiko AR. Hypertension in children. N Engl J Med 1996; 335:1968-73 (PMID: 8960478).
100 Lehnhardt A et al. Pathogenesis, diagnosis and management of hyperkalemia. Pediatr Nephrol 2011; 26: 377-84 (PMID: 21181208).
101 Emanuel B et al. Malaria in children in Chicago. Pediatrics 1993; 92: 83-5 (PMID: 8516089).
102 The renal drug handbook, 3rd and 5th edition. Ashley C et al. Radcliffe Publishing Ltd. 2008 and CRC Press 2019.
103 Empfehlungen zur Diagnose und Behandlung von akuter Otitis media, Sinusitis, Pneumonie (community-acquired) und Tonsillopharyngitis beim Kind / Recommendations pour le diagnostic et le traitement de otite moyenne aiguë, sinusite aiguë, pneumonie (community-acquired) et pharyngo-amygdalite chez l'enfantPediatric Infectious Disease Group of Switzerland PIGS, 2010.
104 Shulman ST et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis 2012; 55(10): e86-102 (PMID: 22965026).
105 Neels HM et al. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med 2004; 42(11):1228-55 (PMID: 15576287).
106 Neues Rezeptur-Formularium NRF. Bundesvereinigung Deutscher Apothekerverbände ABDA (editor). Govi-Verlag, Deutscher Apotheker-Verlag, CD-ROM 2013/1.
107 Vademecum Metabolicum – Diagnose und Therapie erblicher Stoffwechselkrankheiten; 4. Auflage. Zschocke J et al. Milupa Metabolics, Friedrichsdorf, Deutschland, 2012.
108 Tragiannidis A et al. Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation - review of the literature and options for clinical practice. Drugs 2012; 72(5):685-704 (PMID: 22413762).
109 Fusch C et al. Leitlinie Parenterale Ernährung der DGEM, Neonatologie/Pädiatrie. Aktuel Ernaehr Med 2007; 32, Suppl 1: S72-88.
110 Tsuneyoshi I et al. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001; 29(3): 487-93 (PMID: 11373409).
114 Braegger C et al. Vitamin D in the healthy European paediatric population. J Pediatr Gastroenterol Nutr 2013; 56(6): 392-701 (PMID: 23708639).
115 Thalhammer F et al. Prüfung von Stabilität und Kompatibilität von Flucloxacillin (Floxapen) und Ceftazidim (Fortum) in zwei Infusionslösungen: Relevanz für die klinische Praxis. Wien Med Wochenschr 2005; 155(13–14): 337-43 (PMID: 16092041).
116 Pediatric Endocrinology, 4th edition. Firma Lifshitz (editor), Crc Press Inc, 2003.
117 Amlie-Lefond C et al. Thrombolysis in acute childhood stroke: design and challenges of the thrombolysis in pediatric stroke clinical trial. Neuroepidemiology 2009; 32(4): 279-86 (PMID: 19223687).
118 Guidelines for treatment of tuberculosis, World Health Organisation, 4th edition, 2010.
119 Agostoni C et al. Enteral nutrient supply for preterm infants: Commentary from ESPGHAN Committee on Nutrition. JPGN 2010; 50: 85-91 (PMID: 19881390).
120 Dupuis LL et al. Guideline for the Prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 2013; 60:1073-1082 (PMID: 23512831).
121 Gan TJ et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2014; 118(1): 85-113 (PMID: 24356162).
122 Hohlfeld T et al. High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs – pharmacological mechanisms and clinical relevance. Thromb Haemost 2013; 109(5): 825-33 (PMID: 23238666).
123 Schiestl C et al. Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas. Eur J Pediatr 2011; 170(4): 493-501 (PMID: 20936416).
124 Beaulieu MJ et al. A review of Drug Therapy for Neonatal Hypertension. Neonatal Netw 2014; 33(2): 95-100 (PMID: 24589901).
125 Ng YT et al. Intravenous Levetiracetam in children with seizures: a prospective safety study. J Child Neurol 2010; 25(5): 551-5 (PMID: 20413804).
126 Teilbarkeit und Zermörserbarkeit von Medikamenten, Kantonsspital Aarau, 2014.
127 Bundesamt für Gesundheit BAG und Eidgenössische Kommission für Impffragen. Impfempfehlungen für Personen vor und nach Transplantation eines soliden Organs. BAG Bulletin 2014; 8: 155-8.
128 Tobias JD. Continuous infusion of rocuronium in a paediatric intensive care unit. Can J Anasth 1996; 43(4): 353-7 (PMID: 8697549).
129 Ratjen F et al. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010; 65(4): 286-91 (PMID: 19996339).
130 Food and Drug Administration FDA. Product Information of BLOXIVERZ (Neostigmine Methylsulfate Injection), 2013.
131 Roach ES et al. Management of stroke in infants and children: a scientific statement from a special writing group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke 2008; 39(9): 2644-91 (PMID: 18635845).
132 Stroke in childhood. Clinical guidelines for diagnosis, management and rehabilitation. The Paediatric Stroke Working Group, Royal College of Physicians, 2004.
133 Kinderunfall mit rohen Pilzen. Tox Info Suisse, 2015.
134 Gesellschaft für Pädiatrische Onkologie und Hämatologie. NB2004 Trial protocol for risk adapted treatment of children with neuroblastoma, 09/2004.
135 Balice-Bourgois C et al. Evaluation zur Wirksamkeit eines Gels (LET) zur topischen Anästhesie bei einfacher Wundversorgung beim Kind. Paediatrica 2008; 19(2): 30-2.
136 Kleinman ME et al. Part 14: Pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122(18 Suppl 3): 876-908 (PMID: 20956230).
137 Paediatric Nephrology, 2nd edition. Rees L et al. Webb Oxford Specialist Handbooks in Paediatrics. Oxford University Press, Oxford, UK, 2012.
138 Ohls RK et al. A randomized, masked, placebo-controlled study of darbepoetin alfa in preterm infants. Pediatrics 2013; 132(1): e119-127 (PMID: 23776118).
139 Ohls RK et al. A randomized, masked study of weekly erythropoietin dosing in preterm infants. J Pediatr. 2012; 160(5): 790-5.e1 (PMID: 22137666).
140 Costa S et al. How to administrate erythropoietin, intravenous or subcutaneous? Acta Paediatr. 2013; 102(6): 579-83 (PMID: 23414120).
141 Brugada J et al. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace 2013; 15(9): 1337-82. (PMID: 23851511).
142 Pädiatrische Notfall- und Intensivmedizin, 3. Auflage. Nicolai T. Springer Verlag, Heidelberg, Deutschland 2007.
143 Yucel IK et al. Efficacy of very low-dose prostaglandin E1 in duct-dependent congenital heart disease. Cardiol Young 2015; 25(1): 56-62 (PMID: 24168719).
144 Johnson PN et al. Dosing of vasopressin in critically ill children: implications for medication safety. Pediatr Crit Care Med 2016; 17(3): 277-8 (PMID: 26945208).
145 Swisstransplant / CNDO. The Swiss Donation Pathway – Behandlung des pädiatrischen Spenders. Version 3.0, 04/2014.
146 Lindl-Fischer S. Anaphylaxie bei Kindern und Jugendlichen. Ars Medici 2013; 11: 615-8.
147 AWMF S3-Leitlinie 026/022. Lungenerkrankung bei Mukoviszidose - Modul 1. Stand 06/2013. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, Deutschland. Online access 05/2020.
148 Fraisse A et al. Intravenous sildenafil for postoperative pulmonary hypertension in children withcongenital heart disease. Intensive Care Med 2011; 37(3): 502-9 (PMID: 21069290).
149 Steinhorn RH et al. Intravenous sildenafil in the treatment of neonates with persistent pulmonaryhypertension. J Pediatr 2009; 155(6): 841-7 (PMID: 19836028).
150 Stultz JS et al. Intermittent intravenous sildenafil for pulmonary hypertension management in neonates and infants. Am J Health Syst Pharm 2013; 70(5): 407-13 (PMID: 23413163).
151 Garin et al. Surveillance et traitement de la toxoplasmose chez la femme enceinte, le foetus et le nouveau-né. Pediatrie 1989; 44(9): 705-12 (PMID: 2695891).
152 Swissmedic - Arzneimittelinformation. Swissmedic, Schweizerisches Heilmittelinstitut, Switzerland. Online access.
154 Bécourt C et al. Treatment of scabies with oral ivermectin in 15 infants: a retrospective study on tolerance and efficacy, Br J Dermatol. 2013; 169(4): 931-3 (PMID: 23724970).
155 Ranjkesh MR et al. The efficacy of permethrin 5% vs. oral ivermectin for the treatment of scabies, Annals of Parasitology 2013; 59(4): 189-94 (PMID: 24791346).
156 Workowski KA et al. Centers for Disease control and prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64(RR-03): 1-137 (PMID: 26042815).
157 Centers for disease control and prevention (CDC): Medications/ classic scabies/ ivermectin, online access 11/2018.
158 Handbook of Drug Administration via Enteral Feeding Tubes. 3rd edition. White R et al. Pharmaceutical Press, London, Great Britain, 2015.
159 Modifications by PEDeus (e.g. modification due to age definitions, due to standardisations, due to a different wording of indications)
160 Vademecum Antiepilepticum 2015/2016, Pharmakotherapie der Epilepsien. 23. Auflage. Steinhoff B et Bast T. Epilepsiezentrum Kork, Deutsche Gesellschaft für Epileptologie e.V.
161 Glauser T et al. Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: Report of the guideline committee of the American Epilepsy Society, American Epilepsy Society guideline, Epilepsy Currents 2016; 16(1): 48-61 (PMID: 26900382).
162 Chamberlain JM et al. Lorazepam vs diazepam for pediatric status epilepticus, a randomized clinical trial, JAMA 2014; 311(16): 1652-60 (PMID: 24756515).
163 Bruni O et al. Current role of melatonin in pediatric neurology: clinical recommendations. Eur J Paediatr Neurol 2015; 19(2): 122-33 (PMID: 25553845).
164 SwissPedDose, swiss national paediatric database with dosage recommendations for active ingredients. SwissPedDose Association, Zürich, Switzerland. Online access 2019 until today.
165 Vilas-Boas AL et al. Comparison of oral amoxicillin given thrice or twice daily to children between 2 and 59 months old with non-severe pneumonia: a randomized controlled trial. J Antimicrob Chemother 2014; 69: 1954–1959 (PMID: 24648506).
166 Fachinformationsverzeichnis Deutschland. Fachinfo-Service, Germany. Online access.
167 eMC (electronic Medicines Compendium). Summaries of Product Characteristics (SmPC) for healthcare professionals about medicines licensed for use in the United Kingdom (UK). Online access.
168 Warady BA et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. International Society for Peritoneal Dialysis. Peritoneal Dialysis International 2012; 32 Suppl 2: S32-86 (PMID: 22851742).
169 Panel on opportunistic Infections in HIV-exposed and HIV-infected children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. Department of Health and Human Services, USA. Online access 2019 until today.
170 Panel on opportunistic infections in HIV-exposed and HIV-infected children. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Department of Health and Human Services, USA. Online access 2019 until today.
171 Patterson TF et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 63(4): e1-e60 (PMID: 27365388).
172 Capovilla G et al. Treatment of convulsive status epilepticus in childhood: Recommendations of the Italian League Against Epilepsy. Epilepsia 2013; 54(7): 23-34 (PMID: 24099053).
173 Friedman J. Emergency management of the paediatric patient with generalized convulsive status epilepticus. Paediatr Child Health 2011; 16(2): 91-7 (PMID: 22294869).
174 Welch RD et al. Intramuscular midazolam versus intravenous lorazepam for the prehospital treatment of status epilepticus in the pediatric population. Epilepsia 2015; 56(2): 254-62 (PMID: 25597369).
175 The Association of Paediatric Palliative Medicine (APPM) Master Formulary, 4th edition. Jassal SS (editor). Loughborough, UK, 2017.
176 ansm (Agence nationale de sécurité du médicament et des produits de santé). Résumé des caractéristiques du produit (RCP). Online access.
177 Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine, USA. Online access.
178 Battino D et al. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients, part I: phenobarbital, primidone, valproic acid, ethosuximide and mesuximide. Clin. Pharmacokinet. 1995; 29(4): 257-86 (PMID: 8549027).
179 Van der Vorst MM et al. Diuretics in pediatrics: current knowledge and future prospects. Paediatr Drugs 2006; 8(4): 245-64 (PMID: 16898855).
180 Product Information of Ora-Blend SF. Perrigo Australia. Online access 06/2019.
181 Ferrie S et al. Pancreatic enzyme supplementation for patients receiving enteral feeds. Nutr Clin Pract 2011; 26(3): 349-51 (PMID: 21508176).
182

Shlieout G et al. Administration of CREON pancrelipase pellets via gastrostomy tube is feasible with no loss of gastric resistance or lipase activity: an in vitro study. Clin Drug Investig 2011; 31(7): e1-7 (PMID: 21627335).

183

Sandström M et al. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age. Clin Ther 2012; 34(8): 1828-38 (PMID: 22832034).

184 Winter H et al. Esomeprazole for the treatment of GERD in infants ages 1-11 months. J Pediatr Gastroenterol Nutr 2015; 60 Suppl 1: S9-15 (PMID: 26121349).
185 Ziesenitz VC et al. Efficacy and safety of ibuprofen in infants aged between 3 and 6 months. Paediatr Drugs 2017; 19(4): 277-90 (PMID: 28516288).
186 Valproat DHPC – Anwendungseinschränkung und Schwangerschaftsverhütungsprogramm. Swissmedic, Direct Healthcare Professional Communications. Online access 12/2018.
187 Valproat – Patientenbroschüre. Swissmedic, Direct Healthcare Professional Communications. Online access 12/2018.
188 Valproat – Patientenkarte. Swissmedic, Direct Healthcare Professional Communications. Online access 12/2018.
189 Valproat – Jährlich auszufüllendes Formular zur Bestätigung der Risikoaufklärung. Swissmedic, Direct Healthcare Professional Communications. Online access 12/2018.
190 Valproat – Leitfaden für medizinische Fachkräfte. Swissmedic, Direct Healthcare Professional Communications. Online access 12/2018.
191 Valproate DHPC – Restrictions sur l’utilisation et programme de prévention de la grossesse. Swissmedic, Direct Healthcare Professional Communications. Online access 12/2018.
192 Valproate – Brochure patiente. Swissmedic, Direct Healthcare Professional Communications. Online access 12/2018.
193 Valproate – Carte patiente. Swissmedic, Direct Healthcare Professional Communications. Online access 12/2018.
194 Valproate – Formulaire annuel d’accord de soins. Swissmedic, Direct Healthcare Professional Communications. Online access 12/2018.
195 Valproate – Guide à destination des professionnels de santé. Swissmedic, Direct Healthcare Professional Communications. Online access 12/2018.
196 Gelbe Liste, Pharmindex. Nachrichten, Informationen und Datenbanken für Ärzte, Apotheker und andere medizinische Fachkreise. Medizinische Medien Informations GmbH, Deutschland. Online access.
197 DailyMed, official provider of FDA label information. National Library of Medicine (NLM), USA. Online access.
198 Bass JW et al. Twice-daily oral penicillin for treatment of streptococcal pharyngitis: less is best. Pediatrics 2000; 105(2): 423-4 (PMID: 10654966).
199 AWMF S2k-Leitlinie 017/024. Therapie entzündlicher Erkrankungen der Gaumenmandeln – Tonsillitis. Stand 08/2015. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, Deutschland. Online access 12/2019.
200 DEKAs Productinformation. Dekasvitamins.com. Online access 01/2020.
201 Craig JC et al. Antibiotic prophylaxis and recurrent urinary tract infection in children. N Engl J Med 2009; 361(18): 1748-59 (PMID: 19864673).
202 Alsubaie SS et al. Current status of long-term antibiotic prophylaxis for urinary tract infections in children: an antibiotic stewardship challenge. Kidney Res Clin Pract 2019; 38(4): 441-54 (PMID: 31739385).
203 Empfehlungen der Schweizerischen Arbeitsgruppe für Pädiatrische Nephrologie, der Pädiatrischen Infektiologiegruppe Schweiz und der Schweizerischen Gesellschaft für Kinderurologie. Diagnose und Behandlung von Harnwegsinfektionen beim Kind. Paediatrica 2013; 24(4): 10-13.
204 Hui CP. Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Acute otitis externa. Paediatr Child Health 2013; 18(2): 96-101 (PMID: 24421666).
205 Heckmann M et al. Epinephrine treatment of hypotension in very low birth-weight infants. Acta Paediatr 2002; 91(5): 566-70 (PMID: 12113327).
206 Davis AL et al. American College of Critical Care Medicine: clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. Crit Care Med 2017; 45(6): 1061-93 (PMID: 28509730).
207 Ventura AM et al. Double-blind prospective randomized controlled trial of dopamine versus epinephrine as firstline vasoactive drugs in pediatric septic shock. Crit Care Med 2015; 43(11): 2292-302 (PMID: 26323041).
208 Kattwinkel J et al. Part 15: neonatal resuscitation: 2010 American heart association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2010; 122 (18 Suppl 3): S909-19 (PMID: 20956231).
209 Link MS et al. Part 7: adult advanced cardiovascular life support: 2015 American heart association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2015; 132(18 Suppl 2): S444-64 (PMID: 26472995).
210 Marino BS et al. Cardiopulmonary resuscitation in infants and children with cardiac disease: a scientific statement from the American heart association. Circulation 2018; 137(22): e691-e782 (PMID: 29685887).
211 Bialkowski A et al. Intravenous sildenafil in the management of pulmonary hypertension associated with congenital diaphragmatic hernia. Eur J Pediatr Surg 2015; 25(2): 171-6 (PMID: 24163194).
212 Cochius-den Otter S et al. The CoDiNOS trial protocol: an international randomised controlled trial of intravenous sildenafil versus inhaled nitric oxide for the treatment of pulmonary hypertension in neonates with congenital diaphragmatic hernia. BMJ Open 2019; 9(11): e032122 (PMID: 31694851).
213 Al Hadithy AF et al. Stability of sildenafil (Revatio®) dilutions in dextrose 5%. Intensive Care Med 2011; 37(11): 1899 (PMID: 21946926).
214 Senn L et al. Aktualisierte Empfehlungen zur perioperativen Antibiotikaprophylaxe in der Schweiz, 2015. Swissnoso Bulletin 2015; 20(1): 1-8.
215 Rosenfeld RM et al. Clinical practice guideline: acute otitis externa. Otolaryngol Head Neck Surg 2014; 150(1 Suppl): S1-S24 (PMID: 24491310).
216 Oualha M et al. Population pharmacokinetics and haemodynamic effects of norepinephrine in hypotensive critically ill children. Br J Clin Pharmacol 2014; 78(4): 886-97 (PMID: 24802558).
217 Dempsey E et al. The use of cardiotonic drugs in neonates. Clin Perinatol 2019; 46(2): 273-90 (PMID: 31010560).
218 Rizk MY et al. Norepinephrine infusion improves haemodynamics in the preterm infants during septic shock. Acta Paediatr 2018; 107(3): 408-13 (PMID: 28992392).
219 Lampin ME et al. Noradrenaline use for septic shock in children: doses, routes of administration and complications. Acta Paediatr 2012; 101(9): e426-30 (PMID: 22568565).
220 Banca Dati Farmaci dell'AIFA (Agenzia Italiana del Farmaco). Riassunto delle caratteristiche del prodotto. Online access.
221 Corbacioglu S et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 2012 Apr 7; 379(9823):1301-9 (PMID: 22364685).
222 Bonifazi F et al. Diagnosis and treatment of VOD/SOS after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2020; 11(489): 1-13 (PMID: 32318059).
223 Haussmann U et al. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. Haematologica 2006; 91(6): 795-800 (PMID: 16769582).
224 Richardson PG et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant 2010; 16(7): 1005-17 (PMID: 20167278).
225 Additional product information GSASA (Swiss association of public health administration and hospital pharmacists) / Produkt Zusatzinformationen GSASA / Information complémentaire GSASA. Online access via Swiss Drug Compendium / Arzneimittel Kompendium der Schweiz / Compendium des médicaments de la Suisse.
226 Hünseler C et al. Continuous infusion of clonidine in ventilated newborns and infants: a randomized controlled trial. Pediatr Crit Care Med 2014; 15(6): 511-22 (PMID: 24751788).
227 Hayden JC et al. Optimizing clonidine dosage for sedation in mechanically ventilated children: a pharmacokinetic simulation study. Paediatr Anaesth 2019; 29(10): 1002-10 (PMID: 31373752).
228 Ambrose C et al. Intravenous clonidine infusion in critically ill children: dose-dependent sedative effects and cardiovascular stability. Br J Anaesth 2000; 84(6): 794-6 (PMID: 10895758).
229 Kleiber N et al. Hemodynamic tolerance to IV clonidine infusion in the PICU. Pediatr Crit Care Med 2018; 19(8): e409-16 (PMID: 29912068).
230 Capino AC et al. Clonidine for sedation and analgesia and withdrawal in critically ill infants and children. Pharmacotherapy 2016; 36(12): 1290-99 (PMID: 27779775).
231 Malignant hyperthermia association of the United States (MHAUS). Online access.
232 European malignant hyperthermia group (EMHG). Online access.
233 Malignant hyperthermia diagnostic center Switzerland. Online access.
234 Glahn KP et al. Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. Br J Anaesth 2010; 105(4): 417-20 (PMID: 20837722).
235 Litman RS et al. Consensus statement of the malignant hyperthermia association of the United States on unresolved clinical questions concerning the management of patients with malignant hyperthermia. Anesth Analg 2017; 128(4): 652-9 (PMID: 30768455).
236 Hilbert et al. Evidence-based clinical guidelines for eating disorders: international comparison. Curr Opin Psychiatry 2017; 30(6): 423-37 (PMID: 28777107).
237 Dietary reference intakes for vitamin D and calcium. Ross AC et al. (editors). National Academies Press, Washington DS, US, 2011 (PMID: 21796828). Summary tables dietary reference intakes, recommended dietary allowances and adequete intakes: vitamins and elements. Online access.
238 Vidal France - Le site de référence des professionnels de santé. Vidal group, drug information systems, France. Online access.
239 Flynn JT et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 2017; 140(3): e20171904 (PMID: 28827377).
240 Patel P et al. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol 2017; 83(10): 2148-62 (PMID: 28470980).
  PEDeDose prints are possible by print screen.